Choroideremia research: Report and perspectives on the second international scientific symposium for choroideremia
- 8 February 2016
- journal article
- research article
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 37 (3) , 267-275
Abstract
Purpose: To discuss progress in research on choroideremia (CHM) and related retinopathies with special emphasis on gene therapy approaches. Methods: Biomedical and clinical researchers from across the world as well as representatives of the social science research community were convened to the 2nd International Scientific Symposium for Choroideremia in Denver, Colorado in June 2014 to enhance our understanding of CHM and accelerate the translation of research to clinical application for the benefit of those affected by CHM. Results: Pre-clinical research using cell and animal models continues to further our understanding in the pathogenesis of CHM as well as to demonstrate proof-of-concept for gene transfer strategies. With the advent of modern imaging technology, better outcome measures are being defined for upcoming clinical trials. Results from the first gene therapy trial in CHM show promise, with sustained visual improvement over 6 months post-treatment. Current and next-generation gene transfer approaches may make targeted vector delivery possible in the future for CHM and other inherited retinal diseases. Conclusions: While no accepted therapies exist for CHM, promising approaches using viral-vectored gene therapy and cell therapies are entering clinical trials for eye diseases, with gene therapy trials underway for CHM.Keywords
Funding Information
- Alberta Innovates - Health Solutions (201201139)
- Canadian Institutes of Health Research (ETGRD 119190)
- Choroiderema Research Foundation Canada, Inc. (ETGRD 119190)
- Foundation Fighting Blindness, Canada (ETGRD 119190)
This publication has 41 references indexed in Scilit:
- Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy PatientsMolecular Therapy, 2013
- Therapeutic Margins in a Novel Preclinical Model of Retinitis PigmentosaJournal of Neuroscience, 2013
- Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivoJournal of Molecular Medicine, 2013
- Three-Year Follow-up after Unilateral Subretinal Delivery of Adeno-Associated Virus in Patients with Leber Congenital Amaurosis Type 2Ophthalmology, 2013
- Is belief larger than fact: expectations, optimism and reality for translational stem cell researchBMC Medicine, 2012
- Photoreceptor Differentiation following Transplantation of Allogeneic Retinal Progenitor Cells to the Dystrophic Rhodopsin Pro347Leu Transgenic PigStem Cells International, 2012
- Stem cells: roadmap to the clinicJournal of Clinical Investigation, 2010
- Inner Limiting Membrane Barriers to AAV-mediated Retinal Transduction From the VitreousMolecular Therapy, 2009
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Retinal repair by transplantation of photoreceptor precursorsNature, 2006